Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Cyramza ® (ramucirumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Cyramza® (ramucirumab): Use in patients with COVID-19 (Coronavirus disease 2019)
The use of Cyramza (ramucirumab) in patients with COVID-19 has not been studied.
COVID-19 is an infectious respiratory disease caused by SARS-CoV-2, previously referred to as "2019 novel coronavirus."1
Potential Risk and Benefit Considerations
Treating physicians should assess the patient’s individual benefit/risk ratio considering the patient's signs and symptoms, prior medical history, concomitant medications, and other individual factors when making ramucirumab treatment decisions in the context of COVID-19. Ramucirumab dose adjustments, made at the physician’s discretion, should follow the label. Supportive treatment should be provided as clinically indicated and patients monitored appropriately. Drug interactions between ramucirumab and potential COVID-19 treatments should be considered and are described below.2
The following medications are not expected to have a clinically relevant effect on ramucirumab exposure and ramucirumab is not expected to have a clinically relevant effect on the exposure of the following potential-COVID-19 medications
Infectious Disease Resources for COVID-19
For the most current information regarding COVID-19, please refer to the following resources:
Coronavirus disease (COVID-19) outbreak on the regional office of the EU WHO
COVID-19 on the ECDC web page.
European Society for Medical Oncology (ESMO)
1. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization. Accessed March 17, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it
3. Coronavirus disease (COVID-19) outbreak. World Health Organization Europe. Accessed March 20, 2020. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/novel-coronavirus-2019-ncov
4. COVID-19. European Centre for Disease Prevention and Control. Accessed March 20, 2020. https://www.ecdc.europa.eu/en/novel-coronavirus-china
5. European Society for Medical Oncology. Accessed March 23th. https://www.esmo.org/newsroom/covid-19-and-cancer/covid-19-useful-resources
6. [NICE] National Institute for Health and Care Excellence. Coronavirus (COVID-19). Available from: https://www.nice.org.uk/covid-19. Accessed 25 March 2020.
CDC = Centers for Disease Control and Prevention
COVID-19 = coronavirus disease 2019
NCCN = National Comprehensive Cancer Network
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
WHO = World Health Organization
Date of Last Review: 17 March 2020